Evidence map›Paper›PMID 41282529›Full record

ArticleImmuno-oncology technology2025

Sites of metastases before systemic treatment influence progression patterns and survival in stage IV melanoma patients.

I A Vergara, S N Lo, I Li, J W Conway, X Fu, A M Menzies, M S Carlino, R A Scolyer, G V Long, I P da Silva

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immuno-oncology technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

I A VergaraMelanoma Institute Australia, The University of Sydney, Sydney, Australia.
S N LoMelanoma Institute Australia, The University of Sydney, Sydney, Australia.
I LiMelanoma Institute Australia, The University of Sydney, Sydney, Australia.
J W ConwayMelanoma Institute Australia, The University of Sydney, Sydney, Australia.
X FuMelanoma Institute Australia, The University of Sydney, Sydney, Australia.
A M MenziesMelanoma Institute Australia, The University of Sydney, Sydney, Australia.
M S CarlinoMelanoma Institute Australia, The University of Sydney, Sydney, Australia.
R A ScolyerMelanoma Institute Australia, The University of Sydney, Sydney, Australia.
G V LongMelanoma Institute Australia, The University of Sydney, Sydney, Australia.
I P da SilvaMelanoma Institute Australia, The University of Sydney, Sydney, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Metastatic sites influence response rates to immune checkpoint inhibitors (ICI) and survival, suggesting anatomical locations impact treatment outcomes. This study examines how baseline metastatic sites affect progression patterns and survival in melanoma patients receiving first-line ICI or BRAF/MEK inhibitors (BRAF/MEKi). Methods: Metastatic site presence and lesion counts at baseline and progression were captured chronologically for 347 ICI-treated and 210 BRAF/MEKi-treated patients using a novel graph representation. This novel approach enabled systematic comparison of progression patterns post-therapy failure across patients by providing a standardized representation of patterns of progression in patients with distinct clinical histories. Associations of baseline metastatic sites with progression patterns and progression-free survival (PFS) were assessed. Results: Patients with baseline brain metastasis had higher progression rates in the brain (67% for ICI, 61% for BRAF/MEKi) than those without (21% for ICI, 32% for BRAF/MEKi). Among ICI-resistant patients ( Conclusions: Baseline metastatic sites, treatment modality, and resistance type modulate progression patterns and survival in melanoma patients treated with first-line ICI or BRAF/MEKi.

Indexed as

anti-PD-1 therapybrain metastasismetastatic melanomatargeted therapy

Identifiers

PMID41282529
PMCPMC12637396

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.